Clinical Trials Logo

Clinical Trial Summary

The primary hypothesis in this trial is that the treatment with vericiguat 10 mg or 15 mg in patients with HFpEF improves the KCCQ PLS (Kansas City Cardiomyopathy Questionnaire Physical limitation score) compared to placebo after 24 weeks of treatment.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03547583
Study type Interventional
Source Bayer
Contact Bayer Clinical Trials Contact
Phone (+) 1-888-8422937
Email clinical-trials-contact@bayer.com
Status Recruiting
Phase Phase 2
Start date June 15, 2018
Completion date June 15, 2020